Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.
For the
three
months ended in Mar. 2026,
Rapid Micro Biosystems paid$0.00 Mil more to buy back shares than it received from issuing new shares.
It spent$0.01 Mil paying down its debt.
It paid$0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.
It received$0.00 Mil from paying cash dividends to shareholders.
It received$0.26 Mil on other financial activities.
In all, Rapid Micro Biosystemsearned$0.25 Mil on financial activities for the
three
months ended in Mar. 2026.
Rapid Micro Biosystems (NAS:RPID) Cash Flow from Financing Explanation
Cash from financing contains six items:
1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.
Rapid Micro Biosystems's issuance of stock for the
three
months ended in Mar. 2026 was $0.00 Mil.
2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.
Rapid Micro Biosystems's repurchase of stock for the
three
months ended in Mar. 2026 was $0.00 Mil.
3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.
Rapid Micro Biosystems's net issuance of debt for the
three
months ended in Mar. 2026 was $-0.01 Mil.
Rapid Micro Biosystems spent$0.01 Mil paying down its debt.
4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.
Rapid Micro Biosystems's net issuance of preferred for the
three
months ended in Mar. 2026 was $0.00 Mil.
Rapid Micro Biosystems paid$0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.
5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.
Rapid Micro Biosystems's cash flow for dividends for the
three
months ended in Mar. 2026 was $0.00 Mil.
Rapid Micro Biosystems received$0.00 Mil from paying cash dividends to shareholders.
6. Other Financing:
Money spent or earned by company from other financial activities.
Rapid Micro Biosystems's other financing for the
three
months ended in Mar. 2026 was $0.26 Mil.
Rapid Micro Biosystems received$0.26 Mil on other financial activities.
Rapid Micro Biosystems Cash Flow from Financing Related Terms
Rapid Micro Biosystems Cash Flow from Financing Historical Data
* Premium members only.
The historical data trend for Rapid Micro Biosystems's Cash Flow from Financing can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rapid Micro Biosystems Cash Flow from Financing Chart
Rapid Micro Biosystems Cash Flow from Financing Calculation
This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.
Rapid Micro Biosystems's Cash from Financing for the fiscal year that ended in Dec. 2025 is calculated as:
Cash Flow from Financing for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $19.64 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Cash Flow from Financing of $19.64 Mil mean?
Rapid Micro Biosystems (RPID) has a Cash Flow from Financing of $19.64 Mil as of Mar. 2026. Cash Flow from Financing is the amount of cash earned or paid from financing operations. View historical data for Rapid Micro Biosystems and its competitors.
Is Rapid Micro Biosystems' Cash Flow from Financing too high?
Rapid Micro Biosystems' current Cash Flow from Financing is $19.64 Mil. Overall, Rapid Micro Biosystems has a GF Score™ of 59/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Rapid Micro Biosystems' Cash Flow from Financing compare to HYPR and ZOMDF?
Rapid Micro Biosystems' Cash Flow from Financing of $19.64 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow from Financing for a Medical Devices & Instruments company?
A good Cash Flow from Financing depends on the Medical Devices & Instruments industry context. However, Cash Flow from Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow from Financing mean?
A high Cash Flow from Financing can signal that a stock is expensive relative to its fundamentals. Cash Flow from Financing is the amount of cash earned or paid from financing operations. View historical data for Rapid Micro Biosystems and its competitors. Rapid Micro Biosystems's current Cash Flow from Financing is $19.64 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rapid Micro Biosystems stock overvalued right now?
Based on GuruFocus' analysis, Rapid Micro Biosystems (RPID) is currently considered Fairly Valued. The stock's GF Value™ is $1.91, compared to a current price of $2.04 — trading 6.8% above its estimated fair value. The current Cash Flow from Financing is $19.64 Mil. Rapid Micro Biosystems' overall GF Score™ is 59/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow from Financing calculated?
Cash Flow from Financing is calculated from a company's financial statements. For Rapid Micro Biosystems (RPID), the current Cash Flow from Financing is $19.64 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Rapid Micro Biosystems (RPID) Overvalued in 2026?
Based on GuruFocus' analysis, Rapid Micro Biosystems stock appears to be overvalued.
The current stock price of $2.04 is trading 6.8% above its estimated GF Value™ of $1.91.
GuruFocus considers Rapid Micro Biosystems to be Fairly Valued.
Key valuation signals for RPID:
Cash Flow from Financing: $19.64 Mil
GF Value™: $1.91 vs. price of $2.04 (6.8% above fair value)
No single metric tells the full story. See the RPID stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Rapid Micro Biosystems Inc is a life sciences technology company. Its technology uses a sensitive camera and the natural autofluorescence of living cells to identify and quantify microbial growth faster and more accurately than the traditional method, which relies on the human eye. The company develops, manufactures, markets, and sells Growth Direct systems (Systems), proprietary consumables, laboratory information management system (LIMS) connection, and other software and services to address rapid microbial analysis used for quality control in the manufacture of pharmaceuticals, medical devices, and personal care products. Geographically, it generates maximum revenue from the United States, and the rest from Switzerland, Germany, Japan, and all other countries.
59GF Score
Get the complete analysis for RPID
Cash Flow from Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RPID has been successfully added to your 
